Tonix gets FDA alignment on Lyme disease antibody study design
Tweet Send to a Friend
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced it has received official minutes from a Type C meeting with the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


